ALK and non-small cell lung carcinoma: In a single-arm, open-label, multicenter phase 1/2 study conducted with the involvement of adult subjects with histologically confirmed, locally advanced or metastatic NSCLC with crizotinib-resistant ALK-positive rearrangement and receiving 600 mg or 900 mg alectinib (Alecensa®) twice a day in the fixed dose phase, five matched alectinib CSF-plasma concentration pairs were obtained.